{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ffc1fe6b303132625aa8d15/601c2144888747622bf934cb?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Interfant-06 study: Why should we assess end-of-consolidation MRD in infants with ALL?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ffc1fe6b303132625aa8d15/1610359258735-a63b1cbe37cf1820a10557ea7b820632.jpeg?height=200","description":"<p>During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Janine Stutterheim, Princess Máxima Center, Utrecht, NL. We asked, Why should we assess end-of-consolidation measurable residual disease (MRD) in infants with ALL?</p><p><br></p><p>In this podcast, Stutterheim discusses the prognostic value of MRD for survival outcomes at the end of consolidation in infants with ALL. She also discusses the predictive value of MRD status at the end of induction of therapy for selecting different consolidation therapies. Finally, she reports the relationship of MRD status at the end of induction with myeloid markers in the context of selecting myeloid-style therapy. </p>","author_name":"Scientific Education Support"}